These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 24451411)

  • 1. Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center.
    Stephens DM; Ruppert AS; Jones JA; Woyach J; Maddocks K; Jaglowski SM; Andritsos LA; Flynn JM; Grever MR; Lozanski G; Johnson AJ; Muthusamy N; Heerema NA; Byrd JC
    Leukemia; 2014 Jun; 28(6):1365-8. PubMed ID: 24451411
    [No Abstract]   [Full Text] [Related]  

  • 2. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
    Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
    Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.
    Thompson PA; O'Brien SM; Wierda WG; Ferrajoli A; Stingo F; Smith SC; Burger JA; Estrov Z; Jain N; Kantarjian HM; Keating MJ
    Cancer; 2015 Oct; 121(20):3612-21. PubMed ID: 26193999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience.
    Tam CS; Shanafelt TD; Wierda WG; Abruzzo LV; Van Dyke DL; O'Brien S; Ferrajoli A; Lerner SA; Lynn A; Kay NE; Keating MJ
    Blood; 2009 Jul; 114(5):957-64. PubMed ID: 19414856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interphase fluorescence in situ hybridization analysis of del(11)(q23) and del(17)(p13) in chronic lymphocytic leukemia. a study of 40 early-onset patients.
    Doneda L; Montillo M; Intropido L; Tedeschi A; Morra E; Larizza L
    Cancer Genet Cytogenet; 2003 Jan; 140(1):31-6. PubMed ID: 12550755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab.
    Kreuzer KA; Furman RR; Stilgenbauer S; Dubowy RL; Kim Y; Munugalavadla V; Lilienweiss E; Reinhardt HC; Cramer P; Eichhorst B; Hillmen P; O'Brien SM; Pettitt AR; Hallek M
    Leukemia; 2020 Jan; 34(1):296-300. PubMed ID: 31427720
    [No Abstract]   [Full Text] [Related]  

  • 7. Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia.
    Elter T; James R; Busch R; Winkler D; Ritgen M; Böttcher S; Kahl C; Gassmann W; Stauch M; Hasan I; Staib P; Fischer K; Fink AM; Bahlo J; Bühler A; Döhner H; Wendtner CM; Stilgenbauer S; Engert A; Hallek M
    Leukemia; 2012 Dec; 26(12):2549-52. PubMed ID: 22584787
    [No Abstract]   [Full Text] [Related]  

  • 8. Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia.
    Smolej L; Doubek M; Panovská A; Simkovič M; Brychtová Y; Belada D; Motyčková M; Mayer J
    Leuk Res; 2012 Oct; 36(10):1278-82. PubMed ID: 22840362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
    Soumerai JD; Ni A; Xing G; Huang J; Furman RR; Jones J; Sharman JP; Hallek M; Adewoye AH; Dubowy R; Dreiling L; Zelenetz AD
    Leuk Lymphoma; 2019 Jun; 60(6):1438-1446. PubMed ID: 30407886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic lymphocytic leukaemia--moving towards cure?
    Hillmen P
    Lancet; 2010 Oct; 376(9747):1122-4. PubMed ID: 20888976
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapy with the FCR regimen does not overcome chronic lymphocytic leukemia biology: aberrant p53 expression predicts response and survival.
    Zenz T; Stilgenbauer S
    Leuk Lymphoma; 2009 Oct; 50(10):1559-61. PubMed ID: 19701850
    [No Abstract]   [Full Text] [Related]  

  • 12. Gain of the short arm of chromosome 2 (2p gain) has a significant role in drug-resistant chronic lymphocytic leukemia.
    Kostopoulou F; Gabillaud C; Chapiro E; Grange B; Tran J; Bouzy S; Degaud M; Ghamlouch H; Le Garff-Tavernier M; Maloum K; Choquet S; Leblond V; Gabarre J; Lavaud A; Morel V; Roos-Weil D; Uzunov M; Guieze R; Bernard OA; Susin SA; Tournilhac O; Nguyen-Khac F;
    Cancer Med; 2019 Jun; 8(6):3131-3141. PubMed ID: 31066214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.
    Lin TS; Ruppert AS; Johnson AJ; Fischer B; Heerema NA; Andritsos LA; Blum KA; Flynn JM; Jones JA; Hu W; Moran ME; Mitchell SM; Smith LL; Wagner AJ; Raymond CA; Schaaf LJ; Phelps MA; Villalona-Calero MA; Grever MR; Byrd JC
    J Clin Oncol; 2009 Dec; 27(35):6012-8. PubMed ID: 19826119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance.
    Cuneo A; Bigoni R; Rigolin GM; Roberti MG; Bardi A; Cavazzini F; Milani R; Minotto C; Tieghi A; Della Porta M; Agostini P; Tammiso E; Negrini M; Castoldi G
    Haematologica; 2002 Jan; 87(1):44-51. PubMed ID: 11801464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features.
    Woyach JA; Lozanski G; Ruppert AS; Lozanski A; Blum KA; Jones JA; Flynn JM; Johnson AJ; Grever MR; Heerema NA; Byrd JC
    Leukemia; 2012 Jun; 26(6):1442-4. PubMed ID: 22289993
    [No Abstract]   [Full Text] [Related]  

  • 16. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
    Farooqui MZ; Valdez J; Martyr S; Aue G; Saba N; Niemann CU; Herman SE; Tian X; Marti G; Soto S; Hughes TE; Jones J; Lipsky A; Pittaluga S; Stetler-Stevenson M; Yuan C; Lee YS; Pedersen LB; Geisler CH; Calvo KR; Arthur DC; Maric I; Childs R; Young NS; Wiestner A
    Lancet Oncol; 2015 Feb; 16(2):169-76. PubMed ID: 25555420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic significance of TP53 mutations in Chinese patients with chronic lymphocytic leukemia is independent of del(17p13).
    Dong HJ; Zhou LT; Zhu DX; Wang DM; Fang C; Zhu HY; Zhuang Y; Miao KR; Xu W; Li JY
    Ann Hematol; 2011 Jun; 90(6):709-17. PubMed ID: 21113594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with del(17p).
    Lacerda MP; Guedes NR; Yamakawa PE; Pereira AD; Fonseca ARBMD; Chauffaille MLLF; Goncalves MV; Yamamoto M; Rodrigues CA
    Ann Hematol; 2017 Sep; 96(9):1577-1578. PubMed ID: 28597168
    [No Abstract]   [Full Text] [Related]  

  • 19. Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients.
    Stephens DM; Ruppert AS; Weirda WG; Jones JA; Woyach JA; Maddocks K; Jaglowski SM; Andritsos LA; Flynn JM; Grever MR; Lozanski G; Tam C; O'Brien S; Keating MJ; Muthusamy N; Abruzzo LV; Heerema NA; Byrd JC
    Am J Hematol; 2015 Nov; 90(11):967-9. PubMed ID: 26202978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.
    Schilling G; Hansen T; Shimoni A; Zabelina T; Pérez-Simón JA; Gutierrez NC; Bethge W; Liebisch P; Schwerdtfeger R; Bornhäuser M; Otterstetter S; Penas EM; Dierlamm J; Ayuk F; Atanackovic D; Bacher U; Bokemeyer C; Zander A; San Miguel J; Nagler A; Kröger N
    Leukemia; 2008 Jun; 22(6):1250-5. PubMed ID: 18418408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.